Mechanisms Underlying Treatment-Resistant Depression: Exploring Sex-Based Biological Differences

Abstract

Treatment-resistant depression (TRD) represents a severe and complex subtype of major depressive disorder (MDD), affecting approximately 30% of patients who fail to respond adequately to multiple standard antidepressant therapies. While the pathophysiology of TRD remains incompletely understood, emerging evidence suggests that sex-based biological differences might influence its onset, progression, and treatment response. Women are disproportionately affected by depression and are more likely to experience residual symptoms and treatment resistance, potentially due to hormonal fluctuations, immune system differences, and variations in brain circuitry and neuroplasticity. This narrative explores the current literature on the mechanisms underlying TRD, with a particular emphasis on sex-specific biological factors. Key focus areas include dysregulation in neurotransmitters and neurotrophic pathways, inflammation, HPA axis alterations, mitochondrial dysfunction, as well as the influence of sex hormones such as estrogen and progesterone. By highlighting these differences, this review underscores the importance of personalized, sex-informed approaches in the prevention and treatment of TRD and calls for further research to elucidate the biological underpinnings that contribute to sex disparities in treatment outcomes.

Keywords: BDNF: Inflammation; estrogen; metabolism; sex differences; treatment‐resistant depression.